Abstract: S-Substituted derivatives of N-(2-mercapto-2-methylpropanoyl)-cysteine which have the formula ##STR1## are useful as a medicine for suppressing liver disorders.

Abstract: N-substituted .omega.-aminoalkanoyl-.omega.-aminoalkanoic acids and their pharmacologically-acceptable salts (with a base) are useful, e.g., in pharmaceutical-composition form for the treatment or prophylaxis of diseases which are based on inadequate performance of the pancreas, the bile and/or the liver. The compounds are prepared, e.g., by reacting an N-(mono- or di-substituted) .omega.-amino-alkanoic acid with an N-(unsubstituted or monosubstituted) .omega.-aminoalkanoic acid.

Abstract: S-(3-methyl-2-butenyl)cysteine ##STR1## or a pharmaceutically acceptable salt thereof. The compound is an expectorant and can be applied in the form of capsules or dragees, solutions, syrups or suppositories.

Abstract: A method, composition and compounds useful in said compositions for treating the skin and scalp characterized by an excessive secretion of sebum to improve the condition thereof by reducing said excessive secretion of sebum includes topically applying to a human having skin and/or a scalp so characterized a cosmetic composition containing as an active ingredient a derivative of cysteine or cysteamine. The composition contains about 0.1-5 weight percent of said derivative and also contains as a carrier for the active ingredient, water, a mixture of water and a lower alkanol, a lower alkanol, a mixture of a lower alkanol and a cosmetic resin, a reducing agent, a neutralizing agent or a vegetable oil.

Abstract: New substituted acyl derivatives of amino acids which have the general formula ##STR1## are useful as angiotensin converting enzyme inhibitors.

Abstract: Penicillamine compounds of the formula: ##STR1## and of the formula: ##STR2## wherein R.sup.1, R.sup.2, R.sup.3, A and B are as defined hereinafter, and pharmaceutically acceptable acid addition salts thereof are disclosed. II are the products of hydrolysis or alcoholysis of I, and I are in turn the products of dehydration of II or alcohol removal form II. I and II are useful for the treatment of rheumatoid arthritis.

Abstract: New substituted acyl derivatives of amino acids which have the general formula ##STR1## are useful as angiotensin converting enzyme inhibitors.

Abstract: New substituted acyl derivatives of amino acids which have the general formula ##STR1## are useful as angiotensin converting enzyme inhibitors.

Abstract: D-Penicillamine and salts thereof may be prepared by reacting certain aryl amines with 4-thiazolidinecarboxylic acid compounds obtained by splitting the .beta.-lactam ring of penicillin derivatives such as benzylpenicillin or phenoxymethylpenicillin.

Abstract: New substituted acyl derivatives of amino acids which have the general formula ##STR1## are useful as angiotensin converting enzyme inhibitors.

Abstract: This invention relates to the compounds: N-(mercaptoacy)-cysteine represented by the following formula wherein Z is selected from the group consisting of CH.sub.3 --CH<, (CH.sub.3).sub.2 C<, (CH.sub.2).sub.2 < and CH.sub.

Abstract: A novel procedure for the preparation of biotin employing cysteine as the starting material is disclosed. This synthesis involves the formation of the thiophane ring by a 1,3-dipolar addition. By virtue of this process pure d-biotin can be obtained, thus obviating the need for chemical resolution. Novel intermediates are also disclosed.

Abstract: Very pure S-carboxymethyl-L-cysteine is prepared by reacting L-cystine in liquid ammonia with metallic sodium to form the disodium salt of L-cysteine, evaporating the ammonia, reacting the disodium salt of L-cysteine with an aqueous solution of chloroacetic acid and precipitating the S-carboxymethyl-L-cysteine formed by acidifying the reaction mixture. There is employed 0.1 to 10 weight percent of a reducing agent based on the chloroacetic acid.

Abstract: New substituted acyl derivatives of amino acids which have the general formula ##STR1## are useful as angiotensin converting enzyme inhibitors.

Abstract: In the process for preparing an organic compound of the formulaA' -- Xin whichX is an amino group, a hydroxyl group or a carboxyl group, andA' is the remainder of the molecule, from an organic compound of the formulaA -- Xin whichA is the remainder of the molecule which can undergo reaction to form A', by converting A -- X into a compound of the formulaA -- Z -- COORin whichZ is --NH--, --O-- or a direct C--C bond, andR is a radical of the formula ##STR1## IN WHICH Y is a direct C--C single bond, the --CH.dbd.CH-- group or an arylene group,R.sup.1 to R.sup.4 each independently is hydrogen, halogen or an alkyl, aryl, aralkyl, alkoxycarbonyl, alkylaminocarbonyl, arylaminocarbonyl or cycloalkylaminocarbonyl radical, orR.sup.1 + r.sup.2 and R.sup.3 + R.sup.4 each independently completes a 5- or 6-membered carbocyclic ring, orR.sup.1 and R.sup.